A new study published in the International Journal of Molecular Sciences provides fresh evidence that cannabidiol (CBD) could play a distinctive role in the treatment of pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and deadly cancers.
Researchers from the University of Parma, University College Cork, The University of Western Australia, and Curtin University tested the effects of cannabinoids in a mouse model designed to mimic human PDAC. Both delta-9-tetrahydrocannabinol (THC) and CBD were evaluated as single treatments and in combination. While CBD and THC together reduced cell viability in pancreatic cancer cell lines, only CBD as a standalone treatment extended survival in mice.
The team found that the survival benefit with CBD was tied to changes in gut microbiota composition and bile acid metabolism, pointing to a potential link between these biological systems and the cannabinoid’s anticancer effects. Notably, this outcome differed from both THC monotherapy and THC/CBD combinations, highlighting CBD’s unique therapeutic profile.
According to the researchers, CBD’s ability to influence bile acid profiles could help predict which patients might respond to treatment, opening the door to more personalized therapeutic strategies. The findings also suggest that targeting bile acid metabolism itself may represent a new approach for tackling PDAC.
With PDAC survival rates remaining low despite advances in conventional treatment, the study reinforces the importance of exploring cannabinoids—particularly CBD—as part of the ongoing search for novel therapies.
More articles from The Marijuana Herald:
